Table 1.
Summary of select CAR T cell clinical trials targeting the TME
| Strategy/target | Treatment | Cancer type | ClinicalTrials.gov identifier |
|---|---|---|---|
| Enhancing CAR T cell infiltration | |||
| Chemokines | CXCR5-expressing EGFR-CAR T cells | non-small cell lung cancer | NCT04153799 |
| ECM | FAP-CAR T cells | mesothelioma | NCT01722149 |
| tumor vasculature | VEGF-R2-CAR T cells | metastatic melanoma renal cancer |
NCT01218867 |
| local CAR T cell delivery | intracranial Her2-CAR T cells | GBM glioma |
NCT02442297 |
| intratumoral Her2-CAR T cells | GBM glioma |
NCT03389230 | |
| intratumoral B7-H3-CAR T cells | GBM | NCT04077866 | |
| intraventricular NKG2D-CAR T cells | GBM | NCT04717999 | |
| intracranial IL13Ra2-CAR T cells | GBM glioma |
NCT02208362 | |
| intratumoral MG7-CAR T cells | liver metastases | NCT02862704 | |
| intrahepatic artery CEA- CAR T cells | liver metastases | NCT01373047 | |
| intratumoral GPC3-CAR T cells | hepatocellular carcinoma cholangiocarcinoma | NCT04951141 | |
| intratumoral GPC3-CAR T cells | hepatocellular carcinoma | NCT03130712 | |
| intrapleural mesothelin-CAR T cells | mesothelioma lung cancer breast cancer |
NCT02414269 | |
| intratumoral cMet-CAR T cells | breast cancer | NCT01837602 | |
| intratumoral T1E-CAR T cells | head and neck cancer | NCT01818323 | |
| Resisting immunosuppression | |||
| suppressive cytokines or inhibitory signals | TGF-β knockout EGFR-CAR T cells | advanced biliary tract cancer | NCT04976218 |
| TGF-β DNR PSMA-CAR T cells | prostate cancer | NCT04227275 | |
| TGF-β DNR PSMA-CAR T cells | prostate cancer | NCT03089203 | |
| PD1 DNR MSLN-CAR T cells | malignant mesothelioma | NCT04577326 | |
| pro-inflammatory cytokines | IL-12-secreting MUC16ecto- CAR T cells | ovarian cancer | NCT02498912 |
| IL-12-secreting EGFR-CAR T cells | colorectal cancer | NCT03542799 | |
| IL-7/CCL19-secreting CD19-CAR T cells | lymphoma | NCT04833504 | |